San Diego, CA 7/9/2009 10:00:26 PM
Anadys Pharmaceuticals, ANA598, and Money - Analysis at SmallCapNetwork.com
Anadys Pharmaceuticals Inc. (ANDS) has a great hepatitis C test treatment with ANA598... too bad they'll need to raise funds to finish its testing.
Anadys Pharmaceuticals Inc. (ANDS) investors who have been waiting for good news regarding the company's hepatitis C drug program (ANA598) might want to get used to waiting. Given Anadys Pharmaceutical's need for cash before beginning the next phase of testing, and the challenging fund-raising environment, finding a cash-rich development partner may - in retrospect - have been the better and faster solution.
Investors and traders are invited to read further analytical review of Anadys Pharmaceuticals Inc. as well as similar opportunities by subscribing to the free Small Cap Network Newsletter, which offers complete access to all commentary, market trend analysis, trading ideas and other useful market related insights by going to: www.smallcapnetwork.com/s/.
Anadys Pharmaceuticals released the hepatitis C drug's Phase I results in April. ANA598 was an effective antiviral at various doses, but the rashes seen in some of the drug's users raised questions about the safety of the treatment. Several patients dropped out of the study because of the side effect.
About Anadys Pharmaceuticals Inc.
Anadys Pharmaceuticals Inc. (ANDS) is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.
Forward-Looking Statement: This press release may include or imply "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Small Cap Network is not a registered investment advisers or broker/dealer. Small Cap Network makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for many of their securities, investing in such securities is highly speculative and carries a high degree of risk.
Contact Information:
Small Cap Network
4653 Carmel Mtn. Rd
Suite 308 #402
San Diego, CA 92130
Email: editor@smallcapnetwork.com
Source: Small Cap Network
http://community.smallcapnetwork.com/Four-Small-Cap-Biotechs-FDA-Favors-Two-Denies-Two/s/article/view/p/mid/1/id/134/
